TY - JOUR
T1 - Age-dependent germline mosaicism of the most common noonan syndrome mutation shows the signature of germline selection
AU - Yoon, Song Ro
AU - Choi, Soo Kung
AU - Eboreime, Jordan
AU - Gelb, Bruce D.
AU - Calabrese, Peter
AU - Arnheim, Norman
N1 - Funding Information:
Research reported in this publication was supported by the National Institute of General Medical Sciences under award number R01GM36745 (N.A. and P.C.) and the National Heart, Lung and Blood Institute under award number HL071207 (B.D.G.) of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences, National Heart, Lung and Blood Institute, or National Institutes of Health. One of the authors (B.D.G.) has the following conflict of interest: royalty payments for PTPN11 mutation testing for Noonan syndrome from GeneDx, Correlegan, Prevention Genetics, Lab Corp, Baylor College of Medicine and Harvard/Partners. We thank Jon Oatley for helpful discussions and Thomas Myers for Tma31FS DNA polymerase. (Research samples of Tma31FS can be obtained from Dr. Thomas W. Myers, thomas.myers@roche.com , Director, Program in Core Research, Roche Molecular Systems, 4300 Hacienda Drive, Pleasanton, CA 94588.)
PY - 2013/6/6
Y1 - 2013/6/6
N2 - Noonan syndrome (NS) is among the most common Mendelian genetic diseases (∼1/2,000 live births). Most cases (50%-84%) are sporadic, and new mutations are virtually always paternally derived. More than 47 different sites of NS de novo missense mutations are known in the PTPN11 gene that codes for the protein tyrosine phosphatase SHP-2. Surprisingly, many of these mutations are recurrent with nucleotide substitution rates substantially greater than the genome average; the most common mutation, c.922A>G, is at least 2,400 times greater. We examined the spatial distribution of the c.922A>G mutation in testes from 15 unaffected men and found that the mutations were not uniformly distributed across each testis as would be expected for a mutation hot spot but were highly clustered and showed an age-dependent germline mosaicism. Computational modeling that used different stem cell division schemes confirmed that the data were inconsistent with hypermutation, but consistent with germline selection: mutated spermatogonial stem cells gained an advantage that allowed them to increase in frequency. SHP-2 interacts with the transcriptional activator STAT3. Given STAT3's function in mouse spermatogonial stem cells, we suggest that this interaction might explain the mutant's selective advantage by means of repression of stem cell differentiation signals. Repression of STAT3 activity by cyclin D1 might also play a previously unrecognized role in providing a germline-selective advantage to spermatogonia for the recurrent mutations in the receptor tyrosine kinases that cause Apert syndrome and MEN2B. Looking at recurrent mutations driven by germline selection in different gene families can help highlight common causal signaling pathways.
AB - Noonan syndrome (NS) is among the most common Mendelian genetic diseases (∼1/2,000 live births). Most cases (50%-84%) are sporadic, and new mutations are virtually always paternally derived. More than 47 different sites of NS de novo missense mutations are known in the PTPN11 gene that codes for the protein tyrosine phosphatase SHP-2. Surprisingly, many of these mutations are recurrent with nucleotide substitution rates substantially greater than the genome average; the most common mutation, c.922A>G, is at least 2,400 times greater. We examined the spatial distribution of the c.922A>G mutation in testes from 15 unaffected men and found that the mutations were not uniformly distributed across each testis as would be expected for a mutation hot spot but were highly clustered and showed an age-dependent germline mosaicism. Computational modeling that used different stem cell division schemes confirmed that the data were inconsistent with hypermutation, but consistent with germline selection: mutated spermatogonial stem cells gained an advantage that allowed them to increase in frequency. SHP-2 interacts with the transcriptional activator STAT3. Given STAT3's function in mouse spermatogonial stem cells, we suggest that this interaction might explain the mutant's selective advantage by means of repression of stem cell differentiation signals. Repression of STAT3 activity by cyclin D1 might also play a previously unrecognized role in providing a germline-selective advantage to spermatogonia for the recurrent mutations in the receptor tyrosine kinases that cause Apert syndrome and MEN2B. Looking at recurrent mutations driven by germline selection in different gene families can help highlight common causal signaling pathways.
UR - http://www.scopus.com/inward/record.url?scp=84878845351&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2013.05.001
DO - 10.1016/j.ajhg.2013.05.001
M3 - Article
C2 - 23726368
AN - SCOPUS:84878845351
SN - 0002-9297
VL - 92
SP - 917
EP - 926
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 6
ER -